Regulatory Surveillance Over Weight Loss Drug (GLP-1) Supply Chain

Posted On: 24 MAR 2026 10:02AM by PIB Delhi In order to ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug’s unauthorized sale and promotion. With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks. Taking cognizance of the situation, India’s Drugs Controller, in collaboration with State Regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorized sales and use. On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage. In the recent weeks, enforcement activities were significantly scaled up. Audits and inspections were conducted at 49 entities, including: Online pharmacy warehouses, Drug wholesalers, Retailers, Wellness and slimming clinics. These inspections spanned multiple regions across the country and focused on identifying violations related to unauthorized sale, improper prescription practices, and misleading marketing. Further, notices have also been sent to defaulting entities. The Regulator emphasizes that patient safety remains paramount. The misuse of weight loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners. It is important to reiterate here that the drug has been approved in India with condition of prescription by Endocrinologists and Internal Medicine Specialist and for some indications by Cardiologists only. Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws. ***** SR HFW- SALE OF WEIGHT LOSS DRUGS/24 th March 2026/1 (Release ID: 2244252) Visitor Counter : 13547 Read this release in: Urdu , Marathi , हिन्दी , Gujarati Ministry of Health and Family Welfare Regulatory Surveillance Over Weight Loss Drug (GLP-1) Supply Chain Posted On: 24 MAR 2026 10:02AM by PIB Delhi In order to ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug’s unauthorized sale and promotion. With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks. Taking cognizance of the situation, India’s Drugs Controller, in collaboration with State Regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorized sales and use. On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage. In the recent weeks, enforcement activities were significantly scaled up. Audits and inspections were conducted at 49 entities, including: Online pharmacy warehouses, Drug wholesalers, Retailers, Wellness and slimming clinics. These inspections spanned multiple regions across the country and focused on identifying violations related to unauthorized sale, improper prescription practices, and misleading marketing. Further, notices have also been sent to defaulting entities. The Regulator emphasizes that patient safety remains paramount. The misuse of weight loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners. It is important to reiterate here that the drug has been approved in India with condition of prescription by Endocrinologists and Internal Medicine Specialist and for some indications by Cardiologists only. Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws. ***** SR HFW- SALE OF WEIGHT LOSS DRUGS/24 th March 2026/1 (Release ID: 2244252) <span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">In order to ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug’s unauthorized sale and promotion. </span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks. </span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Taking cognizance of the situation, India’s Drugs Controller, in collaboration with State Regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorized sales and use.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">In the recent weeks, enforcement activities were significantly scaled up. Audits and inspections were conducted at 49 entities, including: Online pharmacy warehouses, Drug wholesalers, Retailers, Wellness and slimming clinics. These inspections spanned multiple regions across the country and focused on identifying violations related to unauthorized sale, improper prescription practices, and misleading marketing. Further, notices have also been sent to defaulting entities. </span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The Regulator emphasizes that patient safety remains paramount. The misuse of weight loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">It is important to reiterate here that the drug has been approved in India with condition of prescription by Endocrinologists and Internal Medicine Specialist and for some indications by Cardiologists only. Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws.</span></span></p> <p style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">*****</span></span></p> <p style="text-align:justify"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">SR</span></span></strong></p> <p style="text-align:justify"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">HFW- SALE OF WEIGHT LOSS DRUGS/24th March 2026/1</span></span></strong></p> " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //